Logo
x

Search

Subscribe Now

innate pharma

The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome

The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome

  • February 18, 2025
The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome

The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome

  • January 4, 2024
Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome

Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome

  • November 3, 2023
Innate Pharma Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Lacutamab

Innate Pharma Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Lacutamab

  • October 5, 2023
Innate Pharma Entered into an Exclusive License Agreement with Takeda to Develop Antibody Drug Conjugates for Celiac Disease

Innate Pharma Entered into an Exclusive License Agreement with Takeda to Develop Antibody Drug Conjugates for Celiac Disease

  • April 3, 2023
Innate Pharma Presents Preliminary P-II (TELLOMAK) Trial Results of Lacutamab for the Treatment of Advanced Mycosis Fungoides

Innate Pharma Presents Preliminary P-II (TELLOMAK) Trial Results of Lacutamab for the Treatment of Advanced Mycosis Fungoides

  • September 26, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.